Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

DUBLIN, April 26, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2012.

Financial Highlights Q1 2012(1) $1,107 Product sales million +24% $1,172 Total revenues million +21% Non GAAP operating income $362 million +18% US GAAP operating income $295 million +11% Non GAAP diluted earnings per ADS $1.48 +20% US GAAP diluted earnings per ADS $1.24 +12% Non GAAP cash generation $310 million +49% Non GAAP free cash flow $248 million +60% US GAAP net cash provided by operating activities $257 million +27%

(1)    Percentages compare to equivalent 2011 period.

The Non GAAP financial measures included within this release are explained on page 21, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 18 - 20.

Angus Russell, Chief Executive Officer, commented:

"Shire continues to perform strongly with first quarter results in line with our expectations. Product sales increased 24%, Non GAAP operating income was up 18% and Non GAAP diluted earnings per ADS increased 20% to $1.48. Our focus on demonstrating value to the healthcare system through meeting the needs of our patients is continuing to deliver.

In ADHD, our lead treatments VYVANSE and INTUNIV both increased share versus the prior year in a growing US market and we anticipate VYVANSE sales of over $1 billion for the full year.

Following its launch late last year, FIRAZYR has made a very good start in the US and has added further growth to the strong sales performance of our other rare disease treatments ELAPRASE, VPRIV and REPLAGAL.

Our new regenerative medicine product DERMAGRAFT also performed well, contributing to our overall growth in product sales.

Using our strong balanc
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...   MedeAnalytics today unveils Revenue Integrity, ... visibility to a provider,s "mid-cycle" to optimize revenue ... Powered by the industry,s leading big data platform, ... between patient access and the business office where ... revenue capture, minimize audit risk and prepare providers ...
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/18/2014)... MD (PRWEB) September 18, 2014 A ... shaping system has been approved by the United States Food ... available for widespread purchase in the US, landmark dermatology center ... and only practices on the east coast to use this ... only practice in the Baltimore area to offer patients the ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Members ... online with participating network dentists at UnitedConcordia.com, thanks ... dental wellness company. , "Members can book an ... 'Schedule Now' button located on the Find a ... vice president of network operations at United Concordia. ...
(Date:9/18/2014)... 2014 MD Complete , the ... a prescription, announced today that SHAPE Magazine has named ... “Best Peel” in its annual Beauty Awards. The issue ... beauty products as tested by SHAPE’s expert team. , ... results. Among the thousands of beauty products launched every ...
(Date:9/18/2014)... 2014 One Week Kitchens will have their ... Fair beginning this Saturday. Their display will be inside the ... of the products and design services that are offered at ... for fair-goers to see. This display won ‘Most Beautiful Display’ ... year and really is something to see. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Each year, ... of activities that coincide with National Health IT (NHIT) ... (IT/IS) professionals. To help Norman Regional show its gratitude, ... for hospitals , is contributing giveaway items to support ... a prize drawing and offering free lunches, Norman Regional ...
Breaking Medicine News(10 mins):Health News:New FDA-Approved UltraShape Body Contouring Procedure Comes to Maryland Laser Skin and Vein 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2
... Technologies, Inc. (Nasdaq: EFJI ) today announced its ... revenues decreased $11.5 million, or 34%, to $22.4 million for ... for the same period in 2008. This anticipated quarterly decline ... in revenues associated with the FCC re-banding effort. "While our ...
... May 6 NeoStem, Inc. (NYSE Amex: ... and long-term storage of adult stem cells for future ... proprietary stem cell technology of Vincent C. Giampapa, ... first licensed in February 2009.The newest adult stem cell ...
... Pharmaceuticals Corp., a developer and manufacturer of medical products that ... the first quarter of 2009. , For the quarter ended ... million, or $0.06 cents per share, on revenues of $4.1 ... or $0.12 cents per share, on revenues of $5.2 million ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... cancer and inflammatory diseases, today reported financial results for ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) , The Company ... approximately ($3.5 million), or ($0.04) per share, compared with ...
... cancers at Women,s Dermatologic Society outreach at Family Circle ... safety and skin health, South Carolina physicians representing the ... cancer screenings and education for fans enjoying the Family ... day of outreach, local dermatologists referred 38% of the ...
... May 6 Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... March 31, 2009.In the first quarter of 2009, Micromet ... progress in the clinic and in corporate development. ...
Cached Medicine News:Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 2Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 3Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 4Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 5Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 6Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 3Health News:NUCRYST announces 2009 first quarter financial results 2Health News:NUCRYST announces 2009 first quarter financial results 3Health News:NUCRYST announces 2009 first quarter financial results 4Health News:NUCRYST announces 2009 first quarter financial results 5Health News:NUCRYST announces 2009 first quarter financial results 6Health News:NUCRYST announces 2009 first quarter financial results 7Health News:EntreMed Reports First Quarter 2009 Financial Results 2Health News:EntreMed Reports First Quarter 2009 Financial Results 3Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 9
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
... electronic, motorized rotary microtomes ... applications of paraffin, semi-thin ... specimens in clinical, research, ... instruments display extra-ordinary ergonomic ...
... RM2235 is a robust rotary microtome ... biological specimens embedded in paraffin. The ... micrometer feed system ensures premium quality ... sectioning harder tissues. The RM2235 is ...
Medicine Products: